审核状态: 通过审核 Project audit state: Successful 注册号: ChiCTR2000039545 Registration number: 最近更新时间: 2020/10/31 3:39:46 Date of Last Refreshed on: 注册号状态: 预注册 Registration Status: Prospective registration 填写语言: 中文和英文 Language: Chinese And English 注册题目: EGFR通过磷酸化RAB7A介导代谢重编程调控巨噬细胞极化在脓毒症中的作用及分子机制研究 EGFR regulates macrophage polarization by phosphorylating Rab7A-mediated metabolic reprogramming Study on the role and Public title: molecular mechanism of sepsis 注册题目简写: Public title acronym: 研究课题的正式科学名称: EGFR通过磷酸化RAB7A介导代谢重编程调控巨噬细胞极化在脓毒症中的作用及分子机制研究 EGFR regulates macrophage polarization by phosphorylating Rab7A-mediated metabolic reprogramming Study on the role and Scientific title: molecular mechanism of sepsis 研究课题的正式科学名称简写: Scientific title acronym: 研究课题代号(代码): Study subject ID: 在其它机构的注册号: Secondary ID: 申请注册联系人: 陈翠平 研究负责人: 唐靖 Applicant: chen cui ping Study leader: Tang Jing 申请注册联系人电话: 研究负责人电话: 13729016162 13189091282 Applicant telephone: Study leader's telephone: 申请注册联系人传真: 研究负责人传真: Applicant Fax: Study leader's fax: 申请注册联系人电子邮件: 研究负责人电子邮件: 271783511@qq.com tanglitangjing@126.com Applicant E-mail: Study leader's E-mail: 申请单位网址(自愿提供): 研究负责人网址(自愿提供): Applicant website(voluntary Study leader's website(voluntary supply): supply): 申请注册联系人通讯地址: 广东省湛江市人民大道南57号 研究负责人通讯地址: 广东省湛江市人民大道南57号 57 Renmin Dadao South, Zhanjiang City, 57 Renmin Dadao South, Zhanjiang City, Applicant address: Study leader's address: Guangdong Province, China Guangdong Province, China 申请注册联系人邮政编码: 研究负责人邮政编码: Applicant postcode: Study leader's postcode: 申请人所在单位: 广东医科大学附属医院 Applicant's institution: Affiliated Hospital of Guangdong Medical University 是否获伦理委员会批准: 是 Approved by ethic committee: Yes 伦理委员会批件文号: 伦理委员会批件附件: Approved No. of ethic PJ2020-077 Approved file of Ethical 查看附件View committee: Committee: 批准本研究的伦理委员会名称: 广东医科大学附属医院机构审查伦理委员会 Name of the ethic committee: Review Ethics Committee of Affiliated Hospital of Guangdong Medical University 伦理委员会批准日期: Date of approved by ethic committee: 国家FDA批准文号: 国家FDA批准附件: Approved No. of SFDA: Approved file of SFDA:

国家FDA批准日期: Date of approved by SFDA:

研究实施负责(组长)单位: 广东医科大学附属医院

Primary sponsor:	Affiliated Ho	Spital of Guariguong Medical	Oniversity				
研究实施负责(组长)单位地址:	广东省湛江市	人民大道南57号					
Primary sponsor's address:	57 Renmin I	Dadao South, Zhanjiang City	, Guangdong P	rovince, China			
	国家:	中国	省(直辖 市):	广东	市((区县):	湛江
\	Country:	CHINA	Province:	Guangdong	Cit	y:	Zhanjiang
试验主办单位(项目批准或申办 者): Secondary sponsor:	单位(医 院):	广东医科大学附属医院	具体地址:	人民大道南57号			
	Institution hospital:	Affiliated Hospital of Guangdong Medical University	Address:	57 Renmin Avenue	e South		
经费或物资来源:	自筹经费						
Source(s) of funding:	self-financing						
研究疾病:	脓毒症						
Target disease:	Sepsis						
研究疾病代码:							
Target disease code:							
研究类型:	基础科学研究						
Study type:	Basic Science	ce					
研究所处阶段:	其它						
Study phase:	N/A						
研究目的:	探讨EGFR膜深	定位在脓毒症巨噬细胞活化中的作	F用,以及调控EC	GFR 膜定位的分子机制。			
Objectives of Study:		te the role of EGFR membrar GFR membrane localization.	ne localization	n the activation of s	epsis macroph	ages and	the molecular mechanism
研究设计:	病例对照研究						
	Case-Control study						
Study design:	Case-Contro	ol study					
		ol study 对研究知情同意并签署知情同意	书 ②住院脓毒症	患者 ③男女不限,年龄	18周岁以上 ④无	其他严重	系统疾病的患者
	①患者或家属 ①Patients o		med consent to	the study and sign	the informed c	onsent ②	
纳入标准: Inclusion criteria	①患者或家属 ①Patients o sepsis ③No	对研究知情同意并签署知情同意= r family members give inforr	med consent to bove @Patients	the study and sign without other serio	the informed cous systemic dis	onsent ②	
纳入标准: Inclusion criteria	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompan	对研究知情同意并签署知情同意。 r family members give inforr male or female, age 18 or al 肝肾和造血系统疾病 ②合并恶性 tied by severe heart, liver, ki	med consent to bove ④Patients 肿瘤患者 ③术前 dney and hema	the study and sign without other serio 患有中枢神经系统和心 atopoietic diseases ②	the informed c us systemic dis 理疾病	onsent ② seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompan a central ne	对研究知情同意并签署知情同意- r family members give inforr male or female, age 18 or al 肝肾和造血系统疾病 ②合并恶性	med consent to bove ④Patients 肿瘤患者 ③术前 dney and hema	the study and sign without other serio 患有中枢神经系统和心 atopoietic diseases ②	the informed c us systemic dis 理疾病	onsent ② seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompan a central ne	对研究知情同意并签署知情同意。 r family members give inforr male or female, age 18 or al 肝肾和造血系统疾病 ②合并恶性 nied by severe heart, liver, ki rvous system and mental illn	med consent to bove ④Patients :肿瘤患者 ③术前 dney and hema ness before sur	the study and sign without other serio 患有中枢神经系统和心 atopoietic diseases ②	the informed c us systemic dis 理疾病 ②Patients with	onsent ② seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompan a central ne 从From2020	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or al 肝肾和造血系统疾病 ②合并恶性 nied by severe heart, liver, king rvous system and mental illn 1-10-10至To 2021-10-10	med consent to bove ④Patients :肿瘤患者 ③术前 dney and hema ness before sur	the study and sign s without other serio 患有中枢神经系统和心 atopoietic diseases @ gery	the informed c us systemic dis 理疾病 ②Patients with	onsent ② seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompan a central ne 从From2020 组别:	对研究知情同意并签署知情同意: r family members give informale or female, age 18 or al IFIF MEMORY THE	med consent to bove ④Patients :肿瘤患者 ③术前 dney and hema ness before sur	the study and sign s without other serio 患有中枢神经系统和心 stopoietic diseases @ gery 样本量:	the informed c us systemic dis 理疾病 ②Patients with	onsent ② seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana central ne 从From2020 组别: Group:	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or all 肝肾和造血系统疾病 ②合并恶性 nied by severe heart, liver, kir rvous system and mental illn 1-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患者 Group of patients with se 抽取脓毒症患者的血液	med consent to bove ④Patients: 肿瘤患者 ③术前 dney and hemaness before sur	the study and sign s without other serio 患有中枢神经系统和心 atopoietic diseases @ gery 样本量: Sample s	the informed cous systemic dis 理疾病 ②Patients with size: **COUNTY OF THE PROPERTY OF THE PROP	onsent ② seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana central ne 从From2020 组别: Group: 干预措施:	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or all 肝肾和造血系统疾病 ②合并恶性 nied by severe heart, liver, kir vous system and mental illn 1-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患者 Group of patients with set 抽取脓毒症患者的血液	med consent to bove ④Patients: 肿瘤患者 ③术前 dney and hemaness before sur	the study and sign swithout other serio 患有中枢神经系统和心 stopoietic diseases gery	the informed cous systemic dis 理疾病 ②Patients with size: **CKG:** **CKG:* **CKG:**	onsent ② seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompan a central ne 从From2020 组别: Group: 干预措施: Intervention	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or al 肝肾和造血系统疾病 ②合并恶性 lied by severe heart, liver, kirvous system and mental illn l-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患语 Group of patients with se 抽取脓毒症患者的血液	med consent to bove ④Patients: 肿瘤患者 ③术前 dney and hemaness before sur	the study and sign swithout other serio 患有中枢神经系统和心 stopoietic diseases gery	the informed cous systemic dis 理疾病 ②Patients with size: 代码: tion	onsent @seases	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: 研究实施地点: Countries of recruitment and	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana central ne 从From2020 组别: Group: 干预措施: Intervention	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or all 肝肾和造血系统疾病 ②合并恶性 nied by severe heart, liver, king rvous system and mental ill non-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患者 Group of patients with set 抽取脓毒症患者的血液 non-Collect blood from patien 中国	med consent to bove ④Patients: 肿瘤患者 ③术前 dney and hemaness before surn 者组 epsis tts with sepsis	the study and sign is without other serio 患有中枢神经系统和心 atopoietic diseases @ gery	the informed cous systemic dis 理疾病 ②Patients with size: 代码: tion	onsent ② seases complicat (区县):	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana central ne 从From2020 组别: Group: 干预措施: Intervention 国家: Country: 单位(医	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or all 肝肾和造血系统疾病 ②合并恶性 nied by severe heart, liver, kir rvous system and mental illn n-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患语 Group of patients with se 抽取脓毒症患者的血液 n: Collect blood from patien 中国 China	med consent to bove ④Patients: Imama 3 水前 Imama 3 水前 Imama 4 小前 Imama 5 小前 Imama 6 小前 Imama 7 小	the study and sign is without other serio is without other serio 患有中枢神经系统和心 is stopoietic diseases @ gery	the informed cous systemic dis 理疾病 ②Patients with size: 代码: tion	onsent ② seases complicat (区县):	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: 研究实施地点: Countries of recruitment and	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana central ne 从From2020 组别: Group: 干预措施: Intervention 国家: Country: 单位(医院): Institution	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or all 肝肾和造血系统疾病 ②合并恶性 ided by severe heart, liver, kirvous system and mental illn illn-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患者 Group of patients with se 抽取脓毒症患者的血液 in: Collect blood from patien 中国 China 广东医科大学附属医院 Affiliated Hospital of Guangdong Medical	med consent to bove ④Patients imama ③术前 dney and hemaness before surn also before	the study and sign swithout other serio 患有中枢神经系统和心 stopoletic diseases gery #本量: Sample s 干预措施作 Interven code: 广东 Guangdong 三级甲等	the informed cous systemic dis 理疾病 ②Patients with size: 代码: tion	onsent ② seases complicat (区县):	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: 研究实施地点: Countries of recruitment and	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompan a central ne 从From2020 组别: Group: 干预措施: Intervention 国家: Country: 单位(医院): Institution hospital:	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or all 肝肾和造血系统疾病 ②合并恶性 ided by severe heart, liver, kirvous system and mental illn illn-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患语 Group of patients with se 抽取脓毒症患者的血液 n: Collect blood from patien 中国 China 广东医科大学附属医院 Affiliated Hospital of Guangdong Medical University	med consent to bove ④Patients imama ③术前 dney and hemaness before surn also before	the study and sign swithout other serio 患有中枢神经系统和心 stopoletic diseases gery #本量: Sample s 干预措施作 Interven code: 广东 Guangdong 三级甲等	the informed cous systemic dis 理疾病 ②Patients with Size: ************************************	onsent ② seases complicat (区县): ty:	Hospitalized patients with
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: 研究实施地点: Countries of recruitment and research settings:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana central ne 从From2020 组别: Group: 干预措施: Intervention 国家: Country: 单位(医院): Institution hospital:	对研究知情同意并签署知情同意-r family members give informale or female, age 18 or all 肝肾和造血系统疾病 ②合并恶性 nied by severe heart, liver, king rvous system and mental illustrates and mental illustrates. Group of patients with see 抽取脓毒症患者的血液 n: Collect blood from patients with a China 广东医科大学附属医院 Affiliated Hospital of Guangdong Medical University 表皮生长因子	med consent to bove ④Patients imama ③术前 dney and hemaness before surn also before	the study and sign swithout other serio 患有中枢神经系统和心 stopoletic diseases gery #本量: Sample s 干预措施作 Interven code: 广东 Guangdong 三级甲等	the informed cous systemic dis 理疾病 Patients with size: **COUNTY OF THE PROPERTY OF THE PROP	onsent ② seases complicat (区县): ty:	Thospitalized patients with ted malignant tumor ③He
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: 研究实施地点: Countries of recruitment and research settings:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana a central ne 从From2020 组别: Group: 干预措施: Intervention 国家: Country: 单位(医院): Institution hospital: Outcome:	对研究知情同意并签署知情同意: r family members give informale or female, age 18 or al 肝肾和造血系统疾病②合并恶性 lied by severe heart, liver, kirvous system and mental illn lie-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患: Group of patients with se 抽取脓毒症患者的血液 n: Collect blood from patient 中国 China 广东医科大学附属医院 Affiliated Hospital of Guangdong Medical University 表皮生长因子 epidermal growth factor	med consent to bove ④Patients imama ③术前 dney and hemaness before surn also before	the study and sign swithout other serio 患有中枢神经系统和心 stopoletic diseases gery #本量: Sample s 干预措施作 Interven code: 广东 Guangdong 三级甲等	the informed cous systemic disus systemic disuges. 理疾病 Patients with size: **COUNTY OF THE STATE OF THE S	onsent ② seases complicat (区县): ty:	Thospitalized patients with ted malignant tumor ③He
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: Grountries of recruitment and research settings: 测量指标:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana a central ne 从From2020 组别: Group: 干预措施: Intervention	对研究知情同意并签署知情同意: r family members give informale or female, age 18 or al 肝肾和造血系统疾病②合并恶性 lied by severe heart, liver, kirvous system and mental illn lie-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患: Group of patients with se 抽取脓毒症患者的血液 n: Collect blood from patient 中国 China 广东医科大学附属医院 Affiliated Hospital of Guangdong Medical University 表皮生长因子 epidermal growth factor	med consent to bove ④Patients imama ③术前 dney and hemaness before surn also before	the study and sign swithout other serio 患有中枢神经系统和心 stopoletic diseases gery #本量: Sample s 干预措施作 Interven code: 广东 Guangdong 三级甲等	the informed cous systemic dis 理疾病 Patients with size: 代码: tion 指标类型: Type: 测量方法: Measure	onsent ② seases complicat (区县): ty:	Thospitalized patients with ted malignant tumor ③He
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: GR实施地点: Countries of recruitment and research settings: 测量指标: Outcomes:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana a central ne 从From2020 组别: Group: 干预措施: Intervention Interventio	对研究知情同意并签署知情同意: r family members give informale or female, age 18 or al IFIYATION INTO INTO INTO INTO INTO INTO INTO	med consent to bove ④Patients imama ③术前 dney and hemaness before surn also before	the study and sign is without other serio and	the informed cous systemic dis 理疾病 ②Patients with size: tion 指标类型: Type: 测量方法: Measure method:	onsent ② seases complicat (区县): ty:	Thospitalized patients with ted malignant tumor ③He
纳入标准: Inclusion criteria 排除标准: Exclusion criteria: 研究实施时间: Study execute time: 干预措施: Interventions: Grown criteria: 不可究实施时间: 不可措施: Countries of recruitment and research settings: 测量指标: Outcomes:	①患者或家属 ①Patients o sepsis ③No ①伴有严重心 ①Accompana central ne 从From2020 组别: Group: 干预措施: Intervention 国家: Country: 单位(医院): Institution hospital: Measure time point o outcome: 标本中文名:	对研究知情同意并签署知情同意: r family members give informale or female, age 18 or all 肝肾和造血系统疾病②合并恶性 lied by severe heart, liver, kirvous system and mental illn l-10-10至To 2021-10-10 非脓毒症患者组和脓毒症患语 Group of patients with se 抽取脓毒症患者的血液 n: Collect blood from patien 中国 China 广东医科大学附属医院 Affiliated Hospital of Guangdong Medical University 表皮生长因子 epidermal growth factor of 血液 me: blood	med consent to bove ④Patients imama ③术前 dney and hemaness before surn also before	the study and sign is without other serio altopoletic diseases agery #本量: Sample s 干预措施f Interven code: 广东 Guangdong 三级甲等 Tertiary A	the informed cous systemic dis 理疾病 ②Patients with size: tion 指标类型: Type: 测量方法: Measure method:	onsent ② seases complicat (区县): ty:	Hospitalized patients with ted malignant tumor ③He

征募研究对象情况: 尚未开始 Recruiting status: Pending 年龄范围: Participant age:

最小 Min age 18 岁 years

最大 Max age 80 岁 years

性别: 男女均可 Gender: Both 随机方法(请说明由何人用什么方法 由护士采取真空取血法抽取脓毒症患者的血液 Randomization Procedure (please state who generates the The blood of patients with sepsis is drawn by the nurse by vacuum. random number sequence and by what method): UTN(全球唯一识别码): 盲法: Blinding: 试验完成后的统计结果: Calculated Results ater the Study Completed: 研究负责(组长)单位: Organizer institution (leader institution): 资料收集汇总单位: 0 Data collection Institution: 资料管理单位: 项目组根据研究就进程择期选择具体公开原始数据 Data management Institution: According to the research process, the project team selects the specific release of the original data. 研究者根据受试者的原始观察记录,将数据及时、完整、正确、清晰地输入病例报告表。录入采用相同的数据库系统双人双机录入,之后对数据库 资料分析单位: 进行两遍比对。电子数据文件分类保存,并有多个备份保存于不同磁盘或记录介质上,妥善保存,禁止破坏。 According to the original observation records of the subjects, the researcher will input the data into the case report form timely, complete, correct and clear. The same database system was used for input, and then the database was compared Data analysis Institution: twice. Electronic data files are stored separately and with multiple backups on different disks or recording media. They are properly stored and no damage is allowed.